Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria.
D000328:Adult; D001803:Blood Transfusion; D003676:Deferoxamine / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000139:chemically induced*; D005492:Folic Acid / Q000627:therapeutic use; D005494:Folic Acid Deficiency / Q000188:drug therapy; D006333:Heart Failure / Q000139:chemically induced*; D006432:Hemochromatosis / Q000139:chemically induced*; D006801:Humans; D007018:Hypopituitarism / Q000139:chemically induced*; D007501:Iron / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D011166:Porphyrins / Q000652:urine*; D013156:Splenectomy; D013789:Thalassemia / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology
D011166:Porphyrins; D005492:Folic Acid; D007501:Iron; D003676:Deferoxamine